Semax Research Guide
5mg · Research compound — not for human consumption
Research Overview
Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH), developed to retain neurotropic signaling characteristics without hormonal adrenal activity. Preclinical research has explored its neuroprotective and neurotrophic-associated mechanisms in laboratory models. This is a research compound not intended for human consumption.
Structural & Class Overview
Synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro; CAS 80714-61-0). Hybrid structure combining the ACTH(4-7) fragment at the N-terminus with a C-terminal Pro-Gly-Pro tripeptide added for metabolic stability. Studied as a neuromodulatory/neurotrophic-associated peptide class agent.
General Research Interest
Research interest includes BDNF-associated signaling changes in preclinical models; transcriptional and gene-expression profiling in cerebral ischemia-reperfusion rat models; immunomodulatory and vascular gene expression in brain tissue; neuroprotection studies in laboratory ischemia models; and mechanistic proteomic analyses.
Storage Considerations
General handling for a lyophilized research peptide: keep lyophilized powder frozen, sealed, and protected from light; refrigerate after reconstitution and limit freeze-thaw cycles. For laboratory research use only.
Testing & Quality Considerations
Quality considerations include HPLC purity analysis, mass spectrometry for identity confirmation, and verification against a batch-specific Certificate of Analysis (COA).
References
- Semax affects expression of immune and vascular system genes in rat brain focal ischemia (PMC)
- Brain Protein Expression Profile of the ACTH(4-7)PGP Peptide (Semax) (PMC)
References are provided for scientific context. Linked sources are independent and not affiliated with iNGEN MD.
